Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492721 · ClinicalTrials.gov registry record · Phase 3
Comparing Tissue Adhesives in Port Site Closure
A Phase 3 study of Dermatitis, Contact, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT05492721: Completed Phase 3 study of Dermatitis, Contact, sponsored by The University of Texas Health Science Center, Houston.
NCT05492721 is a Phase 3 study of Dermatitis, Contact that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 180 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05492721, a Phase 3 study of Dermatitis, Contact, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.
Primary Outcome
Contact Dermatitis is defined as erythema or rash around incisions
Conditions Studied
Interventions
- DEVICE 2-Octylcyanoacrylate
- DEVICE N-butyl-2-cyanoacrylate
Study Locations (1)
Texas
- Memorial Hermann - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2025-06-23 |
| Phase | Phase 3 |
What the finished NCT05492721 record still lists
NCT05492721 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Dermatitis, Contact appearing as the primary indexed condition, and to 2 interventions - of which 2-Octylcyanoacrylate is the first listed.
NCT05492721 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05492721 about?
NCT05492721 is a clinical study titled "Comparing Tissue Adhesives in Port Site Closure". This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.
What is the current status of trial NCT05492721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2022-06-29. Estimated completion is 2025-06-23.
What conditions does trial NCT05492721 study?
This clinical trial studies the following conditions: Dermatitis, Contact.
What interventions are being tested in trial NCT05492721?
The interventions under investigation include: 2-Octylcyanoacrylate (DEVICE), N-butyl-2-cyanoacrylate (DEVICE).
Who is sponsoring clinical trial NCT05492721?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05492721 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05492721's enrollment target sits among peer trials
180 1422nd of 2000 higher than 564 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI